Ascomycin derivatives and their use as immunosupprossive agents

Drugs of the Future

Volumn 25, Issue 3, 2000, Pages 269-277

  Hersperger, Rene ^a   Keller, Thomas H ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Pharma AG   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,3 DIMETHYL 1,2 DIOXOPENTYL) 2 PYRROLIDINECARBOXYLIC ACID 3 (3 PYRIDYL)PROPYL ESTER; 32 O [1 (2 HYDROXYETHYL) 5 INDOLYL]ASCOMYCIN; A 119435; ABT 281; ASCOMYCIN; CP 123369; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; L 685818; L 733725; MACROLIDE; PIMECROLIMUS; SDZ 281240; SDZ MDL 987; TACROLIMUS; UNCLASSIFIED DRUG;

DEGENERATIVE DISEASE; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; RESPIRATORY TRACT DISEASE; REVIEW; SKIN DISEASE;

EID: 0034051644     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.03.574454     Document Type: Review

References (75)

1. Aral, T., Koyama, Y., Suenaga, T., Honda, H. Ascomycin, an antifungal antibiotic. J Antibiotics 1962, Ser. A 15: 231-2.
2. Koyama, Y., Hayashi, T., Honda, H. Studies on ascomycin. Ann Rep Inst Food Microbiol, Chiba University 1963, 15: 79-83.
3. Kino, T., Hatanaka, H., Hashimoto, M. et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiotics 1987, 40: 1249-55.
4. Tanaka, H., Kuroda, A., Marusawa, H. et al. Structure of FK506: A novel immunosuppressant isolated from Streptomyces. J Am Chem Soc 1987, 109: 5031-3.
5. Hatanaka, H., Iwami, M., Kino, T., Goto, T., Okuhara, M. FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. I. Taxonomy of the producing strain. J Antibiotics 1988, 41: 1586-91.
6. Hatanaka, H., Kino, T., Miyata, S. et al. FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. II. Fermentation, isolation and physico-chemical and biological characteristics. J Antibiotics 1988, 41: 1592-601.
7. Morisaki, M., Aral, T. Identity of immunosuppressant FR-900520 with ascomycin. J Antibiotics 1992, 45: 126-8.
8. Or, Y.S., Clark, R.F., Qinghua, X. et al. The chemistry of ascomycin: Structure determination and synthesis of pyrazole analogues. Tetrahedron Lett 1993, 49: 8771-86.
9. Borel, J.F., Feurer, C., Gubler, H.U., Stahelin, H. Biological effects of cyclosporin A: A new antilymphocytic agent. Agents Actions 1976, 6: 468-75.
10. Liu, J. Farmer, J.D., Lane, W.S., Friedman, J., Weissman, I., Schreiber, S.L. Calcineurin is a common target of cyclophilincyclosporin A and FKBP-FK506 complexes. Cell 1991, 66: 807-15.
11. Ho, S., Clipstone, N., Timmermann, L. et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996, 80: S40-5.
12. Peters, D.H., Fitton, A., Plosker, G.L., Faulds, D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993, 46: 746-94.
13. Keown, P.A. Emerging indications for the use of cyclosporin in organ transplantation and autoimmunity. Drugs 1990, 40: 315-25.
14. Gremillion, R.B., Posever, J.O., Manek, N., West, J.P., Van Vollen-Hoven, R.F. Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: Initial experience in 12 patients. J Rheumatol 1999, 26: 2332-6.
15. Feutren, G. Clinical experience with Sandimmune (cyclosporine) in autoimmune diseases. Transplant Proc 1992, 24: 55-60.
16. Ruzicka, T., Assmann, T., Homey, B. Tacrolimus: The drug for the turn of the millennium? Arch Dermatol 1999, 135: 574-80.
17. Berth-Jones, J., Henderson, C.A., Munro, C.S. et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study. Br J Dermatol 1997, 136: 527-30.
18. Lock, S.H., Kay, A.B., Barnes, N.C. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 1996, 153: 509-14.
19. Kay, A.B. Immunosuppressive agents in chronic severe asthma. Allergy Proc 1994, 15: 147-50.
20. Ceyhan, B., Sungur, M., Celikel, C.A., Celikel, T. Effect of inhaled ingredients of a commercial cyclosporin A ampoule on airway inflammation. Respiration 1998, 65: 89.
21. Nagai, H., Yamaguchi, S., Tanaka, H., Inagaki, N. Effect of some immunosuppressors on allergic bronchial inflammation and airway hyperresponsiveness in mice. Int Arch Allergy Immunol 1995, 108: 189-95.
22. Eum, S.-Y., Zuany-Amorim, C., Lefort, J., Pretolani, M., Vargaftic, B. Inhibition by the immunosuppressive agent FK506 of antigen-induced airways eosinophilia and bronchial hyperre-activity in mice. Br J Pharmacol 1997, 120: 130-6.
23. Henry, M.L. Cyclospohne and tacrolimus (FK506): A comparison of efficacy and safety profiles. Clin Transplant 1999, 13: 209-20.
24. Mihatsch, M.J., Kyo, M., Morozumi, K., Yamaguchi, Y., Nickeleit, V., Ryffel, B. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol 1998, 49: 356-63.
25. Mollison, K.W., Fey, T.A., Krause, R.A. et al. Nephrotoxicity studies of the immunosuppressants tacrolimus (FK506) and ascomycin in rat models. Toxicology 1998, 125: 169-81.
26. Hooks, M.A. Tacrolimus, a new immunosuppressant - A review of the literature. Ann Pharmacother 1994, 28: 501-11.
27. Dumont, F.J., Staruch, M.J., Koprak., S.L. et al. The immunosuppressive and toxic effects of FK-506 are mechanistically related: Pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med 1992, 176: 751-60.
28. Griffith, J.P., Kim, J.L., Kim, E.E. et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 1995, 82: 507-22.
29. Koch, K., Newborg, M.F., Hanson, D.C. et al. The C-32 triacetyl-L-rhamnose derivative of ascomycin: A potent, orally active macrolactone immunosuppressant. J Med Chem 1995, 38: 1255-8.
30. Mollison, K.W., Fey, T.A., Krause, R.A. et al. Discovery of less nephrotoxic FK506 analogs and determining immunophilin dependence of immunosuppressant nephrotoxicity with a novel single-dose rat cisplatin potentiation assay. J Pharmacol Exp Ther 1997, 283: 1509-19.
31. Sinclair, P.J., Wong, F., Wyvratt, M., Staruch, M.J., Dumont, F. Preparation and in vitro activity of aryl ether derivatives of the FK-506 related immunosuppressive macrolides ascomycin and L-683,742. Bioorg Med Chem Lett 1995, 5: 1035-8.
32. Sinclair, P.J., Wong, F., Staruch, M.J., et al. Preparation and in vitro activities of naphthyl and indolyl ether derivatives of the FK-506 related immunosuppressive macrolide ascomycin. Bioorg Med Chem Lett 1996, 6: 2193-6.
33. Peterson, L.B., Cryan, J.G., Rosa, R. et al. A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. Transplantation 1998, 65: 10-8.
34. Dumont, F.J., Koprak, S., Staruch, M.J. et al. A tacrolimus-related immunosuppressant with reduced toxicity. Transplantation 1998, 65: 18-26.
35. Goulet, M.T., Hodkey, D.W., Staruch, M.J. et al. Alkyl ether analogs of the FK-506 related immunosuppressive macrolide L-683,590 (ascomycin). Bioorg Med Chem Lett 1994, 4: 921-6.
36. Goulet, M.T., Sinclair, P.J., Wong, F. et al. C32-O-phenalkyl ether derivatives of the immunosuppressant ascomycin: A tether length study. Bioorg Med Chem Lett 1999, 9: 2085-8.
37. Armstrong, H.M., Wong, F., Holmes, M.A. et al. Potent immunosuppressive C(32)-O-arylethyl ether derivatives of ascomycin with reduced toxicity. Bioorg Med Chem Lett 1999, 9: 2089-94.
38. Goulet, M.T., McAlpine, S.R., Staruch, M.J. et al. C32-O-Imidazol-2-yl-methyl ether derivatives of the immunosuppressant ascomycin with improved therapeutic potential. Bioorg Med Chem Lett 1998, 8: 2253-8.
39. Brands, K.M., Dolling, U.-H., Jobson, R.B., Marchesini, G., Reamer, R.A., Williams, J.M. Mild aryl ether formation in the semisynthesis of the novel macrolide immunosuppressant L-732,531. J Org Chem 1998, 63: 6721-6.
40. Song, Z., DeMarco, A., Zhao, M. et al. Highly chemoselective trichloroacetimidate-mediated alkylation of ascomycin: A convergent, practical synthesis of the immunosupressant L-733,725. J Org Chem 1999, 64: 1859-67.
41. Becker, J.W., Rotonda, J., Cryan, J.G. et al. 32-Indolyl ether derivatives of ascomycin: Three-dimensional structures of complexes with FK506-binding protein. J Med Chem 1999, 42: 2798-804.
42. Djukanovic, R., Roche, W.R., Wilson, J.W. et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990, 142: 434-57.
43. Corrigan, C.J., Kay, A.B. CD4 T-lymphocyte activation in acute severe asthma. Relationship to disease severity and atopic status. Am Rev Respir Dis 1990, 141: 970-7.
44. Walker, C., Kaegi, M.K., Braun, P., Blaser, K. Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity. J Allergy Clin Immunol 1991, 88: 935-42.
45. Kon, O.M., Kay, A.B. T cells and chronic asthma. Int Arch Allergy Immunol 1999, 118: 133-5.
46. Barnes, P.J. Inhaled glucocorticoids for asthma. N Engl J Med 1995, 332: 868-75.
47. Sihra, B.S., Kon, O.M., Durham, S.R., Walker, S., Barnes, N.C., Kay, A.B. Effect of cyclosporin A on the allergen-induced late asthmatic reaction. Thorax 1997, 52: 447-52.
48. Hersperger, R., Schuler, W., Zenke, G. Preparation and immunosuppressive activity of 32-(O)-acylated and 32-(O)-thioacylated analogues of ascomycin. Bioorg Med Chem Lett 1999, 9: 227-32.
49. Bodor, N. Soft drugs: Principles and methods for the design of safe drugs. Med Res Rev 1984, 4: 449-69.
50. Unpublished results.
51. Elwood, W., Lotvall, J.O., Barnes, P.J., Chung, K.F. Characterization of allergen-induced bronchial hyperresponsiveness and airway inflammation in actively sensitized Brown-Norway rats. J Allergy Clin Immunol 1991, 88: 951-60.
52. Schneider, T. Van Velzen, D., Moqbel, R., Issekutz, A.C. Kinetics and quantitation of eosinophil and neutrophil recruitment to allergic lung inflammation in a Brown-Norway rat model. Am J Respir Cell Mol Biol 1997, 17: 702-12.
53. DiSepio, D., Chandraratna, A.S., Nagpal, S. Novel approaches for the treatment of psoriasis. Drug Discov Today 1999, 4: 222-31.
54. Boguniewicz, M., Leung, D.Y.M. Management of atopic dermatitis. In: Atopic Dermititis: From Pathogenesis to Treatment. Leung. D.Y.M. (Ed.). Springer Verlag: Heidelberg 1996, 185-220.
55. Liem, W.H., McCullough, J. L., Weinstein, G.D. Effectiveness of topical therapy for psoriasis: Results of a national survey. Cutis 1995, 55: 306-10.
56. Kohda, H. Side effects of topical use of steroids. Asian Med J 1996, 39: 583-89.
57. Mrowietz, U. Macrolide immunosuppressants. Eur J Dermatol 1999, 9: 346-51.
58. SCRIP Daily, Nov 24, 1999.
59. Kawashima, M., Nakagawa, H., Ohtsuki, M., Tamaki, K., Ishibashi, Y. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet 1996, 348: 1240-1.
60. Baumann, K. (Sandoz Corp; Sandoz Patent GmbH; Sandoz Erfindungen VmbH). Preparation of FR 520 analogs. EP 465426.
61. Rappersberger, K., Meingassner, J.G., Fialla, R. et al. Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 1996, 106: 701-10.
62. Baumann, K., Emmer, G. (Sandoz AG; Sandoz Patent GmbH; Sandoz Erfindungen VmbH). Preparation of FK506 analogs as drugs. EP 427680.
63. Graul, A., Castañer, J. SDZ-ASM-981. Drugs Fut 1998, 23: 508-11.
64. Grassberger, M., Baumruker, T., Enz, A. et al. A novel anti-inflammatory drug SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology. Br J Dermatol 1999, 141: 264-73.
65. Hultsch, T., Muller, K.D., Meingassner, J.G., Grassberger, M., Schopf, R.E., Knop, J. Ascomycin macrolactam derivative SDZ ASM981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 1998, 290: 501-7.
66. Meingassner, J.G., Grassberger, M., Fahrngruber, H., Moore, H.D., Scuurman, H., Stutz, A. A novel anti-inflammatory drug, SDZASM981, for the topical and oral treatment of skin diseases: In vivo pharmacology. Br J Dermatol 1997, 137: 568-76.
67. Mrowietz, U., Graeber, M., Brautigam, M. et al. The novel ascomycin derivative SDZ ASM981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998, 139: 992-6.
68. Van Leent, E.J.M., Graeber, M., Thurston, M., Wagenaar, A. Effectiveness of the ascomycin macrolactam SDZ ASM981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998, 134:805-9.
69. Mollison, K.W., Fey, T.A., Gauvin, D.A. et al. Discovery of ascomycin analogues with potent topical but weak systemic activity for treatment of inflammatory skin diseases. Curr Pharm Des 1998, 4: 367-79.
70. Mollison, K.W., Fey, T.A., Gauvin, D.A. et al. A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases. J Invest Dermatol 1999, 112: 729-38.
71. Lyons, W.E., George, E.B., Dawson, T.M., Steiner, J.P., Snyder, S.H. Immunosuppressant FK506 promotes neunte outgrowth in cultures of PC12 cells and sensory ganglia. Proc Natl Acad Sci USA 1994, 91: 3191-5.
72. Gold, B.G., Storm-Dickerson, T., Austin, D.R. The immunosuppressant FK506 increases functional recovery and nerve regeneration following peripheral nerve injury. Restor Neurol Neurosci 1994, 6: 287.
73. Gold, B.G., Katoh, K., Storm-Dickerson, T. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. J Neurosci 1995, 15: 7509-16.
74. Steiner, J.P., Connolly, M.A., Valentine, H.L. et al. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nat Med 1997, 3: 421-8.
75. Hamilton, G.S., Steiner, J.P. Immunophilins: Beyond immunosuppression. J Med Chem 1998, 41: 5119-43.